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Abstract: The timing of carotid endarterectomy (CEA) for symptomatic ipsilateral carotid artery stenosis 
has evolved in practice over time. Key landmark trials outlined the benefit of performing CEA in the 
recently symptomatic carotid artery stenosis, defined as revascularisation within 6 months of the index 
neurological event. Further evidence and sub-analysis demonstrate that performing CEA within 2 weeks of 
symptoms has the maximal benefit in reducing stroke free survival and is associated with a safe perioperative 
complication profile. This has translated into guideline recommendations and widespread clinical practice. 
The case for performing urgent CEA (within 48 hours of index neurological event) over early CEA (within 
2 weeks) has been put forward and studied. Data examining perioperative complications for urgent CEA 
are mostly derived from retrospective single series studies. A moderate balance exists in the literature for 
the safety and risk of urgent CEA. Although many studies present acceptable perioperative stroke and 
mortality rates associated with urgent CEA, evidence still exists that the perioperative complications may 
not be insignificant. This is particularly the case if the presenting neurology is a stroke, rather than a 
transient ischaemic attack (TIA) or amaurosis fugax. This should be contextualised in the practice of modern 
aggressive medical therapy with dual antiplatelets and statins, with evidence suggesting a reduction in 
recurrent ischaemic events prior to surgical intervention. Careful patient selection, presenting neurology and 
medical therapy is likely to be a key feature in considering urgent CEA versus early CEA.
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The disease burden arising from stroke remains a global 
epidemiologically important problem. One in eight strokes 
are fatal within 30 days and one in four are fatal within a 
year. It stands as the second largest cause of death globally. 
Thromboembolism arising from an ipsilateral carotid artery 
stenosis is an important aetiological process accounting for 
20% of all strokes (1,2).
Surgical management of the carotid artery stenosis 
introduced in the 1950’s has evolved into an effective 
treatment in preventing stroke. The two landmark 
randomized controlled trials, the European Carotid Surgery 
Trial (ECST) (3) and the North American Symptomatic 
Carotid Endarterectomy Trial (NASCET) (4), have 
demonstrated the relative benefit of carotid endarterectomy 
(CEA) in the recently (within 6 months) symptomatic 
ipsilateral carotid artery stenosis. The findings from these 
trials translated into grade A recommendations from the 
American Heart Association guidelines for performing 
CEA for symptomatic 70–99% carotid artery stenosis 
within 6 months of an ipsilateral non-disabling carotid 
artery ischaemic event (5). Delaying operative intervention 
for 6–8 weeks after a cerebral event was thought to be 
beneficial at that time due to the perceived increased risk of 
haemorrhagic transformation and increased peri-procedural 
risk together with the belief that delaying CEA would allow 
the carotid plaque to stabilise (6,7). Further evidence from 
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pooled analysis of NASCET and ECST demonstrated 
contrary evidence (8). The maximal benefit in preventing 
future transient ischaemic attack (TIA) and stroke was 
shown to be in the first 2 weeks after the initial ischaemic 
event in these trials. Beyond 2 weeks, the benefit of CEA 
fell dramatically for men with >69% stenosis. The 5-year 
absolute risk reduction was 30.2% with a number needed to 
treat (NNT) of 3 to prevent 1 ipsilateral stroke if CEA was 
performed within 2 weeks (7). The NNT doubles to 6 if 
CEA is delayed between 2–4 weeks (7). In females, benefit 
was only seen by performing CEA for >69% stenosis within 
2 weeks (8). Studying the natural history of symptomatic 
carotid artery stenosis, the recurrent neurological event rate 
is highest in the earlier period following an ischaemic event. 
Stroke rate after a TIA is 6.7% at 2 days and 11.7% at 
7 days (9). In a study of 163 patients with symptomatic 
carotid artery stenosis, the recurrent stroke rate was found 
to be 20.9% within 3 days, 6.7% between 3 and 7 days 
and 3.7% between 7 and 14 days (10). Early (<30 days) vs. 
delayed (>30 days) CEA did not differ in the periprocedural 
stroke or death rate [relative risk: 0.92; 95% confidence 
interval (CI): 0.16–5.27; P=1.00] in further NASCET 
analyses (11), providing further support in performing CEA 
within 2 weeks. Naylor contextualised the argument for early 
(within 2 weeks) CEA with insights from a re-analysis of 
NASCET (12), ECST (13) and the Veteran Affairs trial (14). 
This analysis suggests that if CEAs are performed within 
2 weeks even with a 10% perioperative stroke risk, at 5 years 
more strokes will have been prevented than by delaying 
CEA beyond 4 weeks with an associated 0% perioperative 
stroke risk (7,15).
European and North American guidelines provided 
recommendations favouring early CEA (<2 weeks) for 
symptomatic ipsilateral stenoses (16,17). The UK National 
Stroke Strategy advocated performing CEA within 48 hours 
(urgent) in patients with stable neurology (18). Surveying 
practice within the United Kingdom reflected this guidance 
when analysing the UK National Vascular Registry (NVR). 
CEA was performed in only 10% of patients within 2 weeks 
of the index event in 2008, rising to 37% in 2009 and 58% 
in 2014 (19). The median delay from index symptom to 
CEA decreased from 22 days (IQR, 10–56 days) in 2009 to 
12 days (IQR, 7–26 days) in 2014. In examining real world 
practice over time, the earlier concerns regarding increased 
peri-operative complication rates with early CEA were not 
found in this study. As the median time to CEA decreased 
over 6 years in the UK, no corresponding trend towards 
increasing peri-operative complications was observed. The 
overall postoperative 30-day stroke rate and death rates 
after CEA were 1.85% (95% CI: 1.67–2.02) and 0.83% 
(95% CI: 0.71–0.94). The combined 30-day stroke and 
death rate post CEA was 2.31% (95% CI: 2.11–2.50). These 
rates were stable over time. Despite clear guidelines of a 
2-week target, several studies have demonstrated that this 
target is not met. Up to 40% of patients do not have their 
CEA performed within 2 weeks of symptom onset (19). The 
reason for this has been multifactorial. They include a delay 
in access to carotid imaging, long waiting times to theatre, 
delay in referral to a vascular surgeon, delays resulting 
from co-morbidities and a delay in patients seeking medical 
help (20-27). Studying trends reported in the UK National 
Vascular Registry from 2009–2014 found the most common 
delays to be referral to a vascular surgeon, followed by delay 
in the patient seeking medical attention after symptom 
onset and a delay in access to carotid imaging (19). The 
delay times and rank order of delay reasons had not changed 
in the last 3 years of the study period. The most recent 
NVR 2019 report outlined the median time from symptom 
onset to CEA was 12 days (IQR, 7–23 days) (28). Only 
60% of patients were treated within 2 weeks. The median 
delay times were 4 days (IQR, 1–9 days) from symptom 
to referral; 1 day (IQR, 0–5 days) from referral to vascular 
surgeon review; 5 days (IQR, 2–10 days) from vascular 
surgeon review to CEA (28).
The specific question of timing of intervention and 
safety of early CEA has now been investigated in several 
studies beyond the two seminal RCTs and their sub-
analyses. No statistical difference in periprocedural stroke 
rates were found in an international multicentre study 
analysing 145 CEAs performed urgently or early. Groups 
divided into urgent (CEA <48 hours from index cerebral 
event) and early (3–14 days to CEA from index cerebral 
event) were similar in their stroke rate (10.0% vs. 4.1%; 
P=0.260) (29). CEAs performed across 4 different time 
periods from symptom onset (0–2, 3–7, 8–14 and >14 days) 
did not influence peri-operative outcome in a multivariate 
analysis of 761 symptomatic patients [odds ratio (OR) 0.93 
(0.63–1.36), P=0.71] (30). The majority of patients in this 
study had initial non-disabling events (admission Rankin 
score <2 in over 90% of patients). The same finding was 
observed in patients with severe neurological disability 
from the index event (Rankin score >1), with a composite 
stroke and death rate of 4.4%, 1.8%, 4.4% and 2.5% in 
patients undergoing CEA at 0–2, 3–7, 8–14 and >14 days 
respectively (30). The National Norwegian Carotid Study 
examined almost all (99.2%) patients undergoing CEA in 
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Norway between April 2014 and March 2015 (31). The 
composite outcome of 30-day stroke/death rates for CEA 
within 48 hours, 3–7 days, 8–14 days and >14 days from 
index event to operation were 0%, 3.4%, 5.4% and 2.8% 
respectively (31). No statistical difference was observed in 
the complication rate in urgent versus early CEA groups in 
this prospective population study. Ferrero et al. also found 
relatively acceptable perioperative stroke rates for CEAs 
performed within 48 hours. The study investigated 285 
patients in 5 treatment groups (CEA within <48 hours, 
48 hours–2 weeks, 2–4 weeks, 4–8 weeks, 8–24 weeks). The 
stroke rate amongst <48 hour group was 4.2 % which did 
not differ statistically from the other groups (48 h–2 weeks 
=3.2%; 2–4 weeks =0%; 4–8 weeks =3.4%; 8–24 weeks 
=3.8%) (32). In this study, patients were not eligible for 
CEA if they presented with a disabling neurological event 
(modified Rankin score >5), cerebral lesion greater than 
3cm, suspected or confirmed parenchymal haemorrhage 
associated with infarct, occlusion of the middle cerebral 
artery or considered unfit for surgery (American Society 
of Anaesthesia classification grade V). The authors 
concluded that performing CEA within 48 hours is safe in 
appropriately selected patients with non-disabling stroke. 
Ferrero et al. also reported on a series of 176 patients in 
2014 investigating the perioperative risk of urgent CEA 
differentiated by presenting neurological feature—TIA, 
crescendo TIA (cTIA) and stroke in evolution (SIE). The 
stroke/MI death rates at 30 days were 1.8% (TIA), 0% 
(cTIA) and 7.6% (SIE). The higher complication rate in 
SIE was not statistically significant in comparison to TIA 
and cTIA in this study (33).
The argument that performing CEA within 2 weeks 
is both safe and beneficial has now been well established. 
Although favourable results have been published for urgent 
CEA, concerns have been reported in the periprocedural 
risk associated with urgent CEA (<48 hours) compared to 
early CEA (within 2 weeks). The Swedish Vascular Registry 
reported 2,596 CEAs performed for symptomatic carotid 
artery stenosis between May 2008 and May 2011. According 
to time to CEA from the neurological event, patients 
were investigated across 4 groups (0–2, 3–7, 8–14 and 
15–180 days). The corresponding combined stroke/death 
rate was found to be 11.5% (0–2 days), 3.6% (3–7 days), 
4.0% (8–14 days) and 5.4% (15–180 days). Over a 4 fold 
increase risk of stroke/death was seen between the 0–2 day 
group and 3–7 day group (OR: 4.24; 95% CI: 2.07–8.70; 
P<0.001) (34). Further reports from Sweden on the Carotid 
Alarm Study published in 2017 highlighted similar concerns 
regarding urgent CEA. Prospectively studying 418 patients, 
multivariate regression analysis identified urgent CEA 
(<48 hours) as an independent risk factor for death and 
stroke within 30 days of CEA (35). Urgent CEA conferred 
an 8.0% risk of death or stroke versus 2.9% for the 2–14-day 
group. The Vascular Study Group of New England 
(VSGNE) studied outcomes from 989 patients identified in 
their database undergoing symptomatic CEA. Four groups 
according to timing of surgery were identified—group 1, 
<2 days; group 2, 2–5 days; group 3, ≥6 days; group 4, same 
day CEA. Stroke rates after CEA were highest in group 
1 (7.3%; P=0.016) (36). Other adverse outcomes were 
comparable amongst groups. De Rango et al. published a 
systematic review and meta-analysis in 2015 of 47 studies 
investigating carotid revascularisation and timing of 
intervention (37). Of the included studies, 35 were CEA, 7 
on carotid artery stenting and 5 included both. The pooled 
estimate periprocedural stroke risk for TIA subgroup of 
patients was 2.7% for CEA within 48 hours, 1.5% for 
CEA between 0–7 days and 1.6% for CEA <15 days (37). 
However, when analysing patients presenting initially 
with stroke as the index neurological event, the CEA 
periprocedural stroke risk is much higher, particularly 
for the urgent group (<48 hours): 8.0% (<48 hours), 
5.3% (0–7 days), 5.0% (0–15 days) (37). Villwock et al. 
studied the National Inpatient Sample database between 
2002 and 2011, including 59,327 patients having a 
CEA (38). Rates of stroke/TIA were analysed for CEA 
performed within 48 hours or deferred (48 hours–14 days) 
and according to the presence or absence of cerebral 
infarction. Within 48 hours, the death and stroke rates were 
1.3% and 1.7% respectively for infarction, versus 0.4% and 
1.1% without infarction. The death and stroke rates for 
CEA between 48 hours and 14 days were 0.9% and 1.3% 
respectively with infarction, versus 0.8% and 1.8% without 
infarction. The death and perioperative stroke rates were 
very favourable in this study, however the authors do note 
that performing urgent (<48 hours) CEA for patients with 
infarction is associated with a small increase in mortality 
and stroke perioperatively (39).
The risks of perioperative complications with urgent CEA 
has to be contextualised further with the state of modern 
medical therapy. Earlier studies quantifying the risk of 
recurrent stroke in symptomatic carotid artery stenosis may 
have been overestimated in comparison to the contemporary 
strategy of intensive medical therapy with dual antiplatelets 
and statins. Aggressive medical therapy with dual 
antiplatelets and statins reduces the recurrent risk of an 
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early ischaemic event prior to undergoing a CEA (40-42). 
A 5-fold reduction in recurrent neurological events prior to 
CEA has been shown with aggressive medical therapy (42). 
Recent data demonstrated the risk of recurrent early 
neurological event with dual antiplatelet therapy and 
statin pharmacotherapy is reduced to 2.0% within 
2 days, 4% within 7 days and 7.5% within 30 days (41). 
The role medical therapy in the timing of CEA is still 
debated, particularly given that the Management of A 
Therothrombosis with Clopidogrel in High-risk Patients 
(MATCH) trial failed to demonstrate the superiority of dual 
antiplatelets versus clopidogrel monotherapy (43).
The National Institute of Clinical Excellence (NICE) 
recommends time from symptom to intervention within 
14 days (44). The United Kingdom National Vascular 
Registry reported the median time to intervention was 
12 days (IQR, 7–23 days) in 2018 (45). Between 2016 and 
2018, The UK national operative (within 30 days) death 
and/or stroke rate was 2% (45). The evidence has now been 
well established in performing early CEA (within 2 weeks) 
maximising stroke free survival from recurrent ischaemic 
events and has an established safety profile in terms of 
peri-procedural complications. Although there is a relative 
balance of evidence in the literature for urgent CEA (within 
48 hours), the periprocedural risks still remain a concern, 
with complications exceeding 2% for urgent CEA in studies 
reporting the effect of timing on surgical complications. 
This seems to be particularly the case when performing 
CEAs on patients with significant neurology and stroke 
as the index event. Careful patient selection, presenting 
neurology and medical therapy is likely to be a key feature 
in considering urgent CEA versus early CEA.
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